Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study

BACKGROUND: Weekly paclitaxel + ramucirumab (wPTX + RAM) therapy is recommended as the standard second-line chemotherapy regimen for unresectable advanced/recurrent gastric cancer (GC) or esophagogastric junction cancer. Recent subgroup analysis of the RAINBOW trial revealed a higher frequency of se...

Descripción completa

Detalles Bibliográficos
Autores principales: Nara, Katsuhiko, Yamamoto, Takehito, Yamashita, Hiroharu, Yagi, Koichi, Takada, Tappei, Seto, Yasuyuki, Suzuki, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571405/
https://www.ncbi.nlm.nih.gov/pubmed/37833660
http://dx.doi.org/10.1186/s12885-023-11469-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571405/
https://www.ncbi.nlm.nih.gov/pubmed/37833660
http://dx.doi.org/10.1186/s12885-023-11469-y

Ejemplares similares